Latest News for: open-label trial

Edit

New study results reinforce Tagrisso as the backbone therapy for EGFR-mutated lung cancer across stages and settings

Pharmiweb 26 Mar 2025
FLAURA2 is a randomised, open-label, multi-centre, global Phase III trial in the 1st-line treatment of patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) EGFRm NSCLC.
Edit

Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a

Hastings Tribune 25 Mar 2025
ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 2025 ... .
Edit

CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme

ACCESSWIRE 25 Mar 2025
This ongoing study of Berubicin is a multicenter, open-label, randomized controlled study in adult patients with recurrent GBM (WHO Grade IV - IDH Wild-Type), comparing Berubicin to Lomustine, an ...
Edit

CAR-T Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, ...

GetNews 24 Mar 2025
KYV-101 is currently being evaluated in sponsored, open-label, Phase 1/2 trials of KYV-101 in patients with lupus nephritis, an autoimmune disease in which more than half of patients do not achieve a ...
Edit

Exosomes Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, ...

GetNews 19 Mar 2025
Key Takeaways from the Exosomes Pipeline Report In February 2025, Aegle Therapeutics announced a trial is a prospective, open label, randomized, multi-center study, with intra-subject paired- wound ...
Edit

Clinical trials for cutting edge, game-changer heart drug set to begin in India

The Times of India 18 Mar 2025
... Dr Suhas Hardas.The Phase 4 open-label trials would be conducted at Amrita Institute of Medical Sciences and Research in Kochi and a few other sites (currently in process of shortlisting).
Edit

Chronic Spontaneous Urticaria Treatment Market 2034: EMA, PDMA, FDA Approvals, Medication, Clinical Trials, NDA Approval, ...

GetNews 17 Mar 2025
... (EMBARQ-CSU2) In October 2024, Jasper Therapeutics announced the launch of an open-label extension study for CSU, enrolling patients from the BEACON and SPOTLIGHT trials after their initial follow-up.
Edit

Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease

GetNews 15 Mar 2025
The Phase 1b open-label, multi-center trial is designed to evaluate the safety and tolerability of GT-02287 in people with GBA1-PD and idiopathic PD ... The trial will enroll up to 20 participants who will receive GT-02287 daily for three months.
Edit

Myasthenia Gravis Pipeline 2024: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA ...

GetNews 14 Mar 2025
The trial (NCT06038474) was a double-blind, placebo-controlled, crossover study conducted in an open-label format, involving 36 severely symptomatic, heavily pre-treated patients.
Edit

GenFleet Therapeutics Receives Clinical Trial Approval from China’s NMPA for GFS202A, a Bispecific Antibody Targeting ...

GetNews 13 Mar 2025
... National Medical Products Administration has approved the clinical trial application for GFS202A in an open-label, multi-center phase I study treating cancer patients with precachexia and cachexia.
Edit

Tecovirimat is safe but ineffective as treatment for clade II mpox

NIH 12 Mar 2025
The investigators noted that STOMP open-label participants had fewer lesions, but slower clinical resolution than reported from the PALM007 trial.
Edit

Bullous Pemphigoid Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, MOA, ROA, ...

GetNews 12 Mar 2025
In December 2024, Chugai Pharmaceutical announced results of a Phase 1b Open-label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) In September, 2024.
Edit

Alopecia Areata Market to Expand Significantly by 2032, States DelveInsight Report | Pfizer, Suzhou Zelgen ...

GetNews 12 Mar 2025
In February 2025, Q32 Bio halted its Phase II trial for its former lead renal disease candidate ... Instead, Q32 Bio plans to launch an open-label extension of its Phase II SIGNAL-AA trial (NCT06018428).
Edit

Crows Feet Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | ...

GetNews 11 Mar 2025
The multicenter, open-label READY-4 trial focused on assessing the long-term safety of RelabotulinumtoxinA in managing these facial wrinkles.
Edit

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

Pharmiweb 10 Mar 2025
About the 3014-01 Trial. 3014-01 is a Phase 1/2, open-label, multi-center trial to evaluate the safety and preliminary efficacy of HexaBody-CD38 as a monotherapy in patients with relapsed or refractory multiple myeloma and other blood cancers.
×